Gitte Pedersen
Gitte Pedersen is the co-founder of Genomic Expression Inc, a company pioneering the development of sequence based cancer diagnostics. Prior to Genomic Expression, she founded Proximity Venture Advisors, an international business consulting company that serves high tech companies within the Life Science sector. She worked with biotech companies securing licensing deals, reference clients and capital. Her deal resume is north of $1 billion. Proximity Venture Advisors’ clients were among the largest biotech and pharma corporations to some medium sized and ...
Areas of Expertise
Start up
Having raised +$1 million for Genomic Expression, I can short cut some of the process. Includes preparation of pitch deck and financials.
Corporate and Business Development
I have advised small and larger biotech companies as well as the danish government and have an aggregated deal resume of +$1B
Investing Profile
- Investor Overview
- 1-3 investments
- Invests $50,000 per company
- Other Investments
- genomic expression
My Interests
- Health Sectors
- Medical Devices, Digital Health, Biotech, Health IT, Healthcare Delivery, Pharmaceuticals, Diagnostics
- Markets, Health Indications, Health Issues
- Geographies
Experience
Portfolio Company
Pipeline Angels | January 2015 - Current
Pipeline Angels, (http://pipelineangels.com), a network of new and seasoned women investors, is changing the face of angel investing and creating capital for women social entrepreneurs. Pipeline Angels holds a signature bootcamp for new investors and a signature pitch summit for startups looking for funding. 180+ women have graduated from our signature angel investing bootcamp, 20+ companies have secured funding from Pipeline Angels, we had our first exit in under five years, and Pipeline Angels have invested over US$1.7M in women-led for-profit social ventures via our signature pitch summit process.
CEO and Founder
Genomic Expression Inc | July 2010 - Current
Genomic Expression is finding the best drug for the patient and the best patient for the drug by sequencing RNA. Analyzing RNA is able to tell if the tumor will respond to the new immune therapies, which is the only kind of therapy that is a potential cure. The inconvenient truth is that only 1 out of 4 cancer treatments prolong life. For more information pls see www.genomicexpression.com